Acorda Therapeutics Inc. (ACOR)
NASDAQ: ACOR
· Real-Time Price · USD
0.66
-0.21 (-24.14%)
At close: Apr 03, 2024, 3:59 PM
Acorda Therapeutics Revenue Breakdown
| Period Ending | Mar 31, 2024 | Dec 31, 2023 | Sep 30, 2023 | Jun 30, 2023 | Mar 31, 2023 | Dec 31, 2022 | Sep 30, 2022 | Jun 30, 2022 | Mar 31, 2022 | Dec 31, 2021 | Sep 30, 2021 | Jun 30, 2021 | Mar 31, 2021 | Dec 31, 2020 | Sep 30, 2020 | Jun 30, 2020 | Mar 31, 2020 | Dec 31, 2019 | Sep 30, 2019 | Jun 30, 2019 | Mar 31, 2019 | Dec 31, 2018 | Sep 30, 2018 | Jun 30, 2018 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Ampyra Revenue | 11.5M | 18.7M | 15.72M | 16.91M | 12.61M | 27.82M | 21.11M | 18.18M | 14.9M | 22.52M | 20.03M | 21.76M | 20.25M | 25.34M | 27.34M | 26.08M | 20.12M | 40.78M | 37.65M | 44.18M | 41.33M | 66.35M | 139.97M | 150.41M |
| Ampyra Revenue Growth | -38.51% | +18.89% | -7.02% | +34.17% | -54.69% | +31.80% | +16.13% | +21.97% | -33.82% | +12.45% | -7.96% | +7.45% | -20.09% | -7.32% | +4.85% | +29.59% | -50.65% | +8.32% | -14.79% | +6.89% | -37.70% | -52.60% | -6.94% | n/a |
| Inbrija Revenue | 4.72M | 31K | 8.09M | 8.29M | 5.59M | 3.65M | 500K | 27.48M | 3.67M | 10.39M | 7.8M | 6.44M | 5M | 9.33M | 5.83M | 4.71M | 4.35M | 6.14M | 4.89M | 3.01M | 2.8M | 2.8M | 2.84M | 2.89M |
| Inbrija Revenue Growth | +15125.81% | -99.62% | -2.33% | +48.29% | +53.15% | +629.60% | -98.18% | +648.68% | -64.68% | +33.19% | +21.18% | +28.90% | -46.46% | +59.99% | +23.71% | +8.29% | -29.08% | +25.57% | +62.53% | +7.31% | +0.07% | -1.41% | -1.70% | n/a |
| License Revenue Revenue | 23K | 32.56M | 34K | 23K | 11K | n/a | 29.96M | 3.57M | 18.57M | 32.89M | 27.85M | 28.2M | 25.25M | 34.68M | 34.69M | 30.79M | 24.67M | 47.41M | 44.8M | 47.19M | n/a | n/a | n/a | n/a |
| License Revenue Revenue Growth | -99.93% | +95658.82% | +47.83% | +109.09% | n/a | n/a | +740.03% | -80.80% | -43.53% | +18.10% | -1.23% | +11.69% | -27.20% | -0.03% | +12.64% | +24.81% | -47.96% | +5.83% | -5.07% | n/a | n/a | n/a | n/a | n/a |
| Product Revenue | 17.88M | 5.4M | 25.18M | 25.96M | 18.72M | n/a | 3.05M | n/a | 3.96M | 4.08M | 3.6M | 3.59M | 3.62M | 3.48M | 3.4M | 2.82M | 3.43M | 3.09M | 2.92M | 2.86M | n/a | n/a | n/a | n/a |
| Product Revenue Growth | +231.36% | -78.57% | -3.03% | +38.71% | n/a | n/a | n/a | n/a | -2.85% | +13.04% | +0.53% | -0.80% | +3.82% | +2.32% | +20.50% | -17.60% | +11.05% | +5.61% | +2.10% | n/a | n/a | n/a | n/a | n/a |
| Royalty Revenue | 2.39M | n/a | 2.5M | 3.69M | 3.53M | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a |
| Royalty Revenue Growth | n/a | n/a | -32.14% | +4.51% | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a |
Operating Expense Breakdown
| Period Ending | Mar 31, 2024 | Dec 31, 2023 | Sep 30, 2023 | Jun 30, 2023 | Mar 31, 2023 | Dec 31, 2022 | Sep 30, 2022 | Jun 30, 2022 | Mar 31, 2022 | Dec 31, 2021 | Sep 30, 2021 | Jun 30, 2021 | Mar 31, 2021 | Dec 31, 2020 | Sep 30, 2020 | Jun 30, 2020 | Mar 31, 2020 | Dec 31, 2019 | Sep 30, 2019 | Jun 30, 2019 | Mar 31, 2019 | Dec 31, 2018 | Sep 30, 2018 | Jun 30, 2018 | Mar 31, 2018 | Dec 31, 2017 | Sep 30, 2017 | Jun 30, 2017 | Mar 31, 2017 | Dec 31, 2016 | Sep 30, 2016 | Jun 30, 2016 | Mar 31, 2016 | Dec 31, 2015 | Sep 30, 2015 | Jun 30, 2015 | Mar 31, 2015 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Selling, General, and Administrative Revenue | 28.37M | 22.21M | 23.15M | 21.82M | 22.51M | 26.25M | 23M | 30.07M | 26.94M | 28.44M | 29.62M | 32.37M | 33.97M | 32.88M | 39.94M | 38.66M | 41.11M | 41.22M | 48.7M | 50.2M | 52.73M | 36.82M | 43.57M | 44.26M | 47.6M | 39.52M | 40.74M | 49.33M | 51.7M | 58.68M | 54.37M | 53.06M | 51.78M | 52.98M | 51.06M | 52.82M | 48.77M |
| Selling, General, and Administrative Revenue Growth | +27.76% | -4.09% | +6.08% | -3.06% | -14.25% | +14.16% | -23.51% | +11.62% | -5.28% | -3.99% | -8.48% | -4.71% | +3.32% | -17.68% | +3.31% | -5.96% | -0.28% | -15.36% | -2.97% | -4.80% | +43.20% | -15.50% | -1.56% | -7.01% | +20.45% | -3.00% | -17.42% | -4.58% | -11.89% | +7.94% | +2.47% | +2.46% | -2.27% | +3.78% | -3.34% | +8.30% | n/a |
| Research and Development Revenue | 954K | 1.01M | 1.21M | 1.55M | 1.39M | 1.2M | 1.38M | 1.52M | 1.69M | 1.37M | 1.93M | 2.37M | 4.75M | 4.32M | 5.73M | 5.25M | 7.71M | 9.02M | 16.07M | 18.96M | 16.03M | 27.06M | 22.86M | 25.91M | 30.56M | 35.14M | 33.29M | 51.18M | 46.49M | 53.8M | 54.78M | 50.29M | 44.57M | 43.99M | 43.36M | 31.23M | 30.64M |
| Research and Development Revenue Growth | -5.45% | -16.40% | -22.13% | +11.83% | +15.21% | -13.02% | -9.31% | -9.98% | +24.01% | -29.26% | -18.66% | -50.01% | +9.85% | -24.54% | +9.02% | -31.80% | -14.61% | -43.86% | -15.22% | +18.29% | -40.76% | +18.39% | -11.79% | -15.22% | -13.04% | +5.58% | -34.97% | +10.09% | -13.58% | -1.79% | +8.92% | +12.84% | +1.32% | +1.46% | +38.83% | +1.94% | n/a |